Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model
about
Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares.The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulationsResponse of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin.Gatifloxacin, an advanced 8-methoxy fluoroquinolone.Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureusCombination therapy as a tool to prevent emergence of bacterial resistance.Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureusIn vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?What in vitro models of infection can and cannot do.Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.The population dynamics of antimicrobial chemotherapy.Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.Molecular imaging of bacterial infections in vivo: the discrimination of infection from inflammation.New antimicrobial agents as therapy for resistant gram-positive cocci.Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Rifampin combination therapy for nonmycobacterial infections.Prosthetic joint infection: diagnosis and management.A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesExamination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistanceParameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infectionSelection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin.Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes.Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
P2860
Q28345038-307B1A4A-9588-41B0-B910-27F509F6B0F1Q28485988-0E842D69-EF94-4B7F-92CC-4AD73582907AQ31372845-6271D96A-5CE7-46AD-8890-69D100D71DD5Q31975922-93B9AAF9-3497-4A8E-A5FF-4A98898B614EQ33836597-98E896E5-8EEB-4FEC-99C3-5E3D7FF30D51Q33961767-9D086DA2-E979-42A6-9FB3-A62075A7CE52Q33978084-BA50B129-9CD1-4243-8C2E-100C22BC4AFCQ34347908-19A1FB5B-1F8E-41B8-818D-D3AD0712A357Q34443398-5085E22E-0B4D-4739-9A7F-763EA592968AQ34553464-50961E8E-06A7-4B3F-90EF-1CA55C5F4A86Q35123155-04D4FF4F-C989-4F6B-BBE4-302B4DEF57EFQ35132378-70DE21DC-CA86-49F9-91DE-EFC12C72F85CQ35376362-57C9E376-6B61-4A3C-8E9A-1F967B3CC75DQ36683890-AA2F4C57-9F3B-4D42-9805-686B3492AB49Q36953330-3FAC05E4-EC55-4B8A-8635-6964ACC27831Q37624733-D05F5141-332E-429F-A10F-EAA2A9E58A17Q37672039-E6FD23E0-0C8D-439A-95D4-B2EE99C2D73CQ37929757-C366C995-4829-4BE9-84DA-83A7CDC21974Q39559370-581C878A-E778-4554-B068-9ADCE7FF7CA0Q39559760-914C5888-8454-4700-9F3E-0CA4018E9C35Q39784317-6E09BB70-6291-46E1-AE63-E341FB4F587EQ41913615-852F4449-7150-48A4-825A-C16788CBED62Q42743155-31BB124B-F17E-4DFB-B1F2-6118BE5969D4Q43566338-D6817D71-88F1-4EA9-B53C-C49549310A07Q43820901-E129587E-F149-4B07-A422-BF57A41BEB5F
P2860
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Pharmacodynamics of levofloxac ...... in an in vitro infection model
@ast
Pharmacodynamics of levofloxac ...... in an in vitro infection model
@en
type
label
Pharmacodynamics of levofloxac ...... in an in vitro infection model
@ast
Pharmacodynamics of levofloxac ...... in an in vitro infection model
@en
prefLabel
Pharmacodynamics of levofloxac ...... in an in vitro infection model
@ast
Pharmacodynamics of levofloxac ...... in an in vitro infection model
@en
P2093
P2860
P356
P1476
Pharmacodynamics of levofloxac ...... in an in vitro infection model
@en
P2093
P2860
P304
P356
10.1128/AAC.38.12.2702
P407
P577
1994-12-01T00:00:00Z